Study on how genetics and microbiome affect OCD treatment with SSRIs
Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive
NA · Severance Hospital · NCT02431845
This study is testing how genetics and gut bacteria might influence how well people with obsessive-compulsive disorder respond to a common medication called SSRIs.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 19 Years to 70 Years |
| Sex | All |
| Sponsor | Severance Hospital (other) |
| Locations | 1 site (Seoul) |
| Trial ID | NCT02431845 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the relationship between genetic variants, microbiome, and the response to selective serotonin reuptake inhibitors (SSRIs) in patients with obsessive-compulsive disorder (OCD). It will recruit 200 drug-naive or drug-free participants aged 19 to 70, who will receive SSRIs tailored to their individual needs. Evaluations will be conducted at baseline, 4 months, 6 months, and 1 year after treatment using various psychological scales and functional MRI for some participants. Blood samples will be collected for genetic, proteomic, and microbiomic analyses to explore predictors of treatment response.
Who should consider this trial
Good fit: Ideal candidates are adults aged 19 to 70 with a diagnosis of OCD who are drug-naive or have been drug-free for more than three months.
Not a fit: Patients with neurological disorders, comorbid psychotic disorders, or substance dependence within the past six months may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized treatment strategies for OCD, improving patient outcomes.
How similar studies have performed: While there have been studies on SSRIs and OCD, the specific integration of (epi)genetics and microbiome analysis in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. age 19\~ 70 2. OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV) 3. drug naive or drug free for more than 3 months Exclusion Criteria: 1. any neurological disorder 2. comorbid psychotic disorders 3. alcohol or other substance dependence within past 6 months 4. any evidences for brain diseases
Where this trial is running
Seoul
- Yonsei Univ. Health System Severance Hospital — Seoul, South Korea (RECRUITING)
Study contacts
- Principal investigator: Se Joo Kim, M.D. — Professor, Department of Psychiactry, Yonsei Univ. College of Medicine
- Study coordinator: Se Joo Kim, M.D.
- Email: kimsejoo@yuhs.ac
- Phone: +82-2-2228-1627
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obsessive-Compulsive Disorder, Pharmacogenetics, Microbiome, Proteome